swipe right and left to see the full table

Study TitleProtocol TitleSponsorSummaryStatus
Prospective, historically controlled study to evaluate the efficacy and safety of a newpediatric formulation of nifurtimox in children aged 0 to 17 years with Chagas’ disease.16027.Bayer AG, D-51368 Leverkusen.Prospective study of a pediatric nifurtimox formulation for Chagas’ disease.Recruitment closed //
Follow-up subjects.
Randomized, double - blind, placebo -controlled, phase 3 study of 12 months to assess the efficacy and safety of MK-7264 in adult participants with chronic
cough (PN030).
MK-7264-030.Merck Sharp & Dohme Corp E.Chronic cough in adults.
Phase 3 study of MK-7264 in adult participants with chronic cough.
Recruitment closed //
Follow-up subjects.
Fixed-dose, controlled study of TEV-50717 (deutetrabenazine) for the treatment of tics associated with Tourette's syndrome.TV50717-CNS-30047.Teva Branded PharmaceuticalProducts R&D, Inc.Patients of both sexes, between 6 and 16 years of age (inclusive), with tics associated with Tourette's syndrome (ST). Study to test whether TEV-50717 is effective in relieving tics associated with Tourette's syndrome.Recruitment closed //
Follow-up subjects.
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Ustekinumab in Subjects with Active Systemic Lupus Erythematosus.CNTO1275SLE3001.Janssen Research & Development, LLC.Study to evaluate the efficacy, safety, and tolerability of ustekinumab in subjects between 16 (unless local regulations do not allow it) and 75 years of age,
with positive SLE for active autoantibodies
Recruitment closed //
Follow-up subjects.
Double-blind, placebo-controlled, single-dose ascending study to assess the safety, tolerability and pharmacokinetics of MK-1654 in full-term and premature infants.MK-1654-002-02.Merck Sharp & Dohme Corp E.Phase 1b study on the safety and PK of MK-1654 in full-term and premature infants.Recruitment on going.
A phase 3, open-label,
randomized, multicenter, controlled trial to evaluate the pharmacokinetics and pharmacodynamics of
edoxaban and to compare the efficacy and safety of edoxaban with standard of care anticoagulant therapy in pediatric subjects from birth to less than 18 years of age with confirmed venous
thromboembolism (vte).
DU176b-D-U312Daiichi Sankyo, Inc.Study in pediatric subjects with venous thromboembolism to test the efficacy of Edoxaban.Recruitment on going.
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of MEDI8897, a Monoclonal Antibody with an Extended Half-life Against Respiratory Syncytial Virus, in Healthy Late Preterm and Term Infants (MELODY).D5290C00004MedImmune, LLC, a wholly owned subsidiary ofAstraZeneca PLC.Study D5290C00004 (MELODY) to determine if MEDI8897 will prevent medically attended RSV - confirmed LRTI in healthyinfants entering their first RSV season.Regulatory phaseInvima.
Study randomized, double-blind, controlled with placebo to evaluate the effects of bempedoic acid (etc-1002) in the occurrence of major cardiovascular events in patients with cardiovascular disease or with high risk of non - development.1002-043Esperion Therapeutics, Inc.Study to evaluate the effects of bempedoic acid (etc-1002) in the occurrence of major cardiovascular events in patients with cardiovascular disease or with high risk of non - development.Recruitment closed.
A Phase 3 Randomized, Placebo - Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescentand Adult Subjects with Moderate to Severe Atopic Dermatitis.M16-045AbbVie Inc.Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic DermatitisRecruitment closed// Follow-up subjects
Randomized, double-blind,
placebo - controlled, phase 3 study of 12 months to assess the efficacy and safety of MK-7264 in adult participants with chronic cough (PN030).
CSL112_3001CSL Behring LLC (CSLB)Study to investigate the efficacy and safety of CSL112 in patients with the acute coronary syndrome.Recruitment on going.
A prospective epidemiological study of women between 24-27 weeks of pregnancy to describe pregnancyoutcomes and events of interest in the mother
andneonate, as well as determine
incidence in infants of RSVLRTI
and RSV hospitalization.
207636 (EPI-RSV-008 BOD)GlaxoSmithKline Biologicals SAStudy of pregnancy outcomes and of events of interest in pregnant women, neonates and infants (PEPNI).Recruitment on going.
A multicenter, prospective, randomized, open - label,
blinded - endpoint, Phase 4
study to evaluate the efficacyand safety of sacubitril / valsartan compared with enalaprilon
morbidity, mortality, and NT- proBNP change in patientswith chronic Chagas’ cardiomyopathy.
CSL112_3001CSL Behring LLC (CSLB)Study to investigate the efficacy and safety of CSL112 in patients with the acute coronary syndrome.Recruitment on going.
Cardiovascular Risk Factors and Treatment in General Practice
Patients in Latin America (CARLA): An Epidemiological Study.
A2581203PfizerCardiovascular Risk Factors and Treatment in General Practice
Patients in Latin America (CARLA): An Epidemiological Study.
Recruitment closed// Follow-up subjects.
GLOBAL AWARE – Emerging Markets (EM) (Adults with AtopicDermatitis Reporting on Their Experience in
Emerging Markets
OBS15591Sanofi Aventis Group, SAGAn international observational study in emerging markets to
estimate the burdenof illness in adult atopic dermatitis patients.
Regulatory phaseSponsor
A global registry to study the demographics, socioeconomic and clinical factors, etiologies,
pathophysiology, management, barriers to care, and outcomes of heart failure patients.
NAHamilton Health Sciences through Population Health Research InstituteRegistry with long term follow‐up for the global Congestive Heart Failure (G‐CHF).Recruitment closed// Follow-up subjects.
Multizonal observational study conducted byclinIcal practitioners on Repatha® use iN subjectswith hyperlipIdemia - ZERBINI20160327AmgenStudy to describe the clinical characteristics of subjects prior to initiation of Repatha.Recruitment on going.
Prevalence of Zika virus
sero-reactivity and assessment of the DPP® Zika IgM assay to detect incident Zika virus infection.
ARBO-004 substudy of ZIKA-002GeneOneZika IgM assay to detect incident Zika virus infection in patients’ adultsRecruitment closed